市場調查報告書

即時檢驗(POC)檢驗行業分析報告:產品/技術/處方/應用/最終用途/區域前景/應用潛力/價格趨勢/競爭性市場份額和預測(2020-2026)

Point of Care Testing Market Size By Product, By Technology, By Prescription, By Application, By End-use, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026

出版商 Global Market Insights Inc. 商品編碼 969427
出版日期 內容資訊 英文 400 Pages
商品交期: 2-3個工作天內
價格
即時檢驗(POC)檢驗行業分析報告:產品/技術/處方/應用/最終用途/區域前景/應用潛力/價格趨勢/競爭性市場份額和預測(2020-2026) Point of Care Testing Market Size By Product, By Technology, By Prescription, By Application, By End-use, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026
出版日期: 2020年11月05日內容資訊: 英文 400 Pages
簡介

全球護理點(POC)測試市場是醫療保健和醫療設備領域最重要的垂直市場之一,預計在未來幾年內將顯著增長。由於全球慢性病的發病率以及老年人口的迅速增加,對先進診斷方法和技術的需求正在增加。

本報告調查並分析了全球護理點(POC)檢查市場,並分析了市場概況,按細分/地區劃分的市場趨勢,市場規模趨勢和預測,市場推動者和障礙。它提供系統的信息,例如市場前景,競爭狀況和主要公司的概況。

目錄

第1章調查方法和範圍

  • 市場定義
  • 市場估計和預測參數
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 預測參數
  • 數據驗證
  • 數據源
    • 小學
    • 中學

第2章執行摘要

  • 護理點(POC)檢驗市場的全方位概述
    • 業務趨勢
    • 產品趨勢
    • 技術趨勢
    • 處方趨勢
    • 應用趨勢
    • 最終使用趨勢
    • 區域趨勢

第3章現場檢查(POC)檢查行業的考慮

  • 行業細分
  • 行業狀況
  • 行業影響因素
    • 生長因子
    • 行業中的潛在風險和挑戰
  • 增長潛力分析
    • 副產品
    • 技術
    • 根據處方
    • 按應用
    • 最終用途
  • COVID-19的影響分析
  • 價格分析:按心臟標記
  • 監管狀態
  • 技術狀況
  • 公司股份分析
    • 全球市場份額分析
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 全球市場份額分析:按設置/應用
  • 公司的全球市場份額分析:按設置/應用
    • F. Hoffmann-La Roche Ltd
    • 雅培
    • 約翰遜和約翰遜
    • 西門子股份公司
    • 背屈
  • 波特分析
  • 競爭形勢
    • 公司矩陣分析
  • PESTEL分析

第4章護理點(POC)檢驗市場:按產品

  • 主要細分市場的趨勢
  • 血糖監測
    • 市場規模:按地區
    • 稱重儀器
    • 柳葉刀
  • 心血管代謝檢查產品
    • 市場規模:按地區
    • 心臟標誌物測試產品
    • 血氣/電解質測試產品
    • HBA1C測試產品
  • 傳染病檢查產品
    • 市場規模:按地區
    • 流感檢測產品
    • 艾滋病檢查產品
    • 丙型肝炎測試產品
    • 性感染(STD)測試產品
    • 醫療感染(HAI)測試產品
    • 呼吸道感染檢查產品
    • 熱帶病檢查產品
    • 其他傳染病檢查產品
  • 凝血測試產品
    • 市場規模:按地區
    • PT/INR測試產品
    • 活化凝血時間(ACT/APTT)測試產品
  • 懷孕和生育能力測試產品
    • 市場規模:按地區
    • 驗孕產品
    • 生育力測試產品
  • 腫瘤/癌標誌物檢查商品
  • 尿液檢查檢查產品
  • 膽固醇測試產品
  • 血液檢查產品
  • 藥物濫用(DoA)測試產品
  • 糞便潛伏期測試產品
  • 其他產品

第5章即時醫療點(POC)檢驗市場:按技術

  • 主要細分市場的趨勢
  • 橫向流動分析
    • 市場規模:按地區
  • 浸油桿
  • 微流體
  • 分子診斷
  • 免疫學檢查
  • 聚集測定
  • 流經
  • 固相
  • 生物傳感器

第6章護理點(POC)檢驗市場:通過處方

  • 主要細分市場的趨勢
  • OTC檢查
    • 市場規模:按地區
  • 基於處方的檢查

第7章即時醫療點(POC)檢驗市場:通過應用

  • 主要細分市場的趨勢
  • 心血管代謝測試
    • 市場規模:按地區
  • 傳染病檢查
  • 腎臟檢查
  • 藥物濫用(DoA)測試
  • 血糖測試
  • 驗孕
  • 癌症生物標誌物測試
  • 其他應用

第8章護理點(POC)檢驗市場:最終用途

  • 主要細分市場的趨勢
  • 醫院
    • 市場規模:按地區
  • 診斷中心
  • 研究
  • 家庭醫療
  • 其他

第9章即時醫療點(POC)檢驗市場:按地區

  • 主要區域趨勢
  • 北美
    • 市場規模:按國家
    • 市場規模:按產品
    • 市場規模:按技術
    • 市場規模:按處方
    • 市場規模:按應用
    • 市場規模:按最終用途
    • 美國
    • 加拿大
  • 歐洲
    • 市場規模:按國家
    • 市場規模:按產品
    • 市場規模:按技術
    • 市場規模:按處方
    • 市場規模:按應用
    • 市場規模:按最終用途
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 意大利
  • 亞太地區
    • 市場規模:按國家
    • 市場規模:按產品
    • 市場規模:按技術
    • 市場規模:按處方
    • 市場規模:按應用
    • 市場規模:按最終用途
    • 中國
    • 日本
    • 印度
    • 澳大利亞
  • 拉丁美洲
    • 市場規模:按國家
    • 市場規模:按產品
    • 市場規模:按技術
    • 市場規模:按處方
    • 市場規模:按應用
    • 市場規模:按最終用途
    • 巴西
    • 墨西哥
  • 中東和非洲
    • 市場規模:按國家
    • 市場規模:按產品
    • 市場規模:按技術
    • 市場規模:按處方
    • 市場規模:按應用
    • 市場規模:按最終用途
    • 南非
    • 沙特阿拉伯

第10章公司簡介

  • Abaxis, Inc.
  • Abbott Laboratories
  • Accubiotech Co, Ltd.
  • ACON Laboratories, Inc.
  • Becton, Dickinson and Company
  • Biolytical Laboratories
  • BioMrieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation (HemoCue)
  • Dexcom, Inc
  • Dragerwerk Ag & Co
  • LifeScan IP Holdings, LLC
  • Medtronic
  • Meridian Bioscience, Inc
  • Nova Biomedical
  • Orasure Technologies, Inc
  • F Hoffmann-La Roche Ltd
  • Siemens Healthineers
  • Sysmex Corporation
  • Trinity Biotech
目錄
Product Code: 3086

Title:
Point of Care Testing Market Size By Product (Glucose Monitoring, Cardiometabolic Testing, Infectious Disease Testing, Coagulation Testing, Pregnancy and Fertility Testing, Tumor/Cancer Marker Testing, Urinalysis Testing, Cholesterol Testing, Hematology Testing, Drugs-of-Abuse Testing, Fecal Occult Testing), By Technology (Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics, Immunoassays, Agglutination Assays, Flow-Through, Solid Phase, Biosensors), By Prescription (OTC Testing, Prescription-based Testing), By Application (Cardio Metabolic Testing, Infectious Disease Testing, Nephrology Testing, Drug-of-Abuse (DoA) Testing, Blood Glucose Testing, Pregnancy Testing, Cancer Biomarker Testing), By End-use (Hospitals, Diagnostic Centers, Research Laboratories, Home-Care Settings), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026.

One of the most crucial verticals within the healthcare and medical devices space, global point of care testing market is slated to witness exponential growth over the next few years. The rapid increase in occurrence of chronic diseases and a large geriatric population across the globe has augmented the need for advanced diagnostic procedures and technologies.

In terms of the product landscape, global point of care testing industry is segmented into glucose monitoring, infectious diseases testing products, cardiometabolic testing products, coagulation testing products, tumor & cancer marker testing products, pregnancy & fertility testing products, drug-of-abuse testing products, hematology testing products, and cholesterol testing products.

Cardiometabolic testing market size was pegged at USD 2.5 billion in 2019. The test provides a clinically relevant evaluation to help identify a patient's risk for cardiovascular inflammation, progression towards type 2 diabetes (pre-diabetes), and atherosclerotic cardiovascular disease (ASCVD).

Considering the technology, global point of care testing market is bifurcated into lateral flow assays, biosensors, dipsticks, flow-through, microfluidics, immunoassays, molecular diagnostics, agglutination assays, and solid phase. The biosensors technology segment is projected to be worth more than US$11.8 billion by 2026.

On the basis of prescription, global point of care testing industry is divided into OTC testing and prescription based testing. The prescription based testing segment is poised to grow at a CAGR of over 7.4% through 2026.

The market is classified into cardiometabolic testing, nephrology testing, infectious disease testing, blood glucose testing, drug-of-abuse testing, cancer biomarker testing, and pregnancy testing based on applications. Blood glucose testing application segment accounted for more than 42.2% revenue share of global point of care testing market during 2019 and is likely to witness notable growth by 2026.

Blood glucose testing is an important procedure that measures glucose levels in the blood. Glucose is a type of sugar which is the main source of energy for the human body. Too little or too much glucose in the blood can lead to numerous critical conditions and complications. High blood glucose levels, also known as hyperglycemia, can indicate diabetes that can further increase the risk of heart diseases, kidney failure, blindness, and other complications. On the other hand, low blood glucose levels or hypoglycemia can cause major health problems such as brain damage.

Hospitals, research laboratories, diagnostic centers, and homecare settings are among the different end-users of point of care testing products. Global point of care testing industry size from home care settings is estimated to reach an annual valuation of over US$10.1 billion by 2026. This can be attributed to growing adoption of different diagnostic and testing products among consumers in homecare settings due to convenience and ease-of-use.

From a regional point of view, Latin America captured over 5.6% revenue share of global point of care market testing in 2019 and will grow substantially by 2026. The point of care testing industry in Middle East and Africa is likely to witness a healthy CAGR of nearly 7.7% through the same period.

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definitions
  • 1.2 Base estimates & working
    • 1.2.1 North America
    • 1.2.2 Europe
    • 1.2.3 Asia Pacific
    • 1.2.4 Latin America
    • 1.2.5 Middle East & Africa
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data Sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Point of care testing industry 360 degree synopsis, 2015-2026
    • 2.1.1 Business trends
    • 2.1.2 Product trends
    • 2.1.3 Technology trends
    • 2.1.4 Prescription trends
    • 2.1.5 Application trends
    • 2.1.6 End-use trends
    • 2.1.7 Regional trends

Chapter 3 Point of Care Testing Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2015 - 2026
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Upward trend in disease prevalence among developing countries
      • 3.3.1.2 Surging number of pathology labs and services equipped with advanced diagnostic equipment in North America
      • 3.3.1.3 Technological advancements
      • 3.3.1.4 Increasing R&D investment
      • 3.3.1.5 Growing geriatric population base globally
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 High cost of product development
  • 3.4 Growth potential analysis
    • 3.4.1 By product
    • 3.4.2 By technology
    • 3.4.3 By prescription
    • 3.4.4 By application
    • 3.4.5 By end-use
  • 3.5 COVID-19 impact analysis
  • 3.6 Pricing analysis, by cardiac markers, 2019
  • 3.7 Regulatory landscape
  • 3.8 Technology landscape
  • 3.9 Company share analysis, 2019
    • 3.9.1 Global market share analysis, 2019
    • 3.9.2 North America
    • 3.9.3 Europe
    • 3.9.4 Asia Pacific
    • 3.9.5 Latin America
    • 3.9.6 Middle East and Africa
  • 3.10 Global market share analysis, by settings and application, 2019
  • 3.11 Company global market share analysis, by setting and application, 2019
    • 3.11.1 F. Hoffmann-La Roche Ltd
    • 3.11.2 Abbott
    • 3.11.3 Johnson and Johnson
    • 3.11.4 Siemens AG
    • 3.11.5 Abaxis
  • 3.12 Porter's analysis
  • 3.13 Competitive landscape, 2019
    • 3.13.1 Company matrix analysis
  • 3.14 PESTEL analysis

Chapter 4 Point of Care Testing Market, By Product

  • 4.1 Key segment trends
  • 4.2 Glucose monitoring
    • 4.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.2.2 Strips
      • 4.2.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.2.3 Meters
      • 4.2.3.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.2.4 Lancets
      • 4.2.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.3 Cardiometabolic testing products
    • 4.3.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.3.2 Cardiac marker testing products
      • 4.3.2.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.2 High-sensitivity troponin I (hsTnl)
        • 4.3.2.2.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.3 Brain natriuretic peptide (BNP)
        • 4.3.2.3.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.4 D-dimer
        • 4.3.2.4.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.5 Creatine kinase-MB (CK-MB)
        • 4.3.2.5.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.6 Myoglobin
        • 4.3.2.6.1 Market size, by region, 2015 - 2026 (USD Million)
      • 4.3.2.7 Others
        • 4.3.2.7.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.3.3 Blood Gas/Electrolytes testing products
      • 4.3.3.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.3.4 HBA1C testing products
      • 4.3.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.4 Infectious disease testing products
    • 4.4.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.2 Influenza testing products
      • 4.4.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.3 HIV testing products
      • 4.4.3.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.4 Hepatitis C testing products
      • 4.4.4.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.5 Sexually transmitted disease (STD) testing products
      • 4.4.5.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.6 Healthcare-associated Infection (HAI) testing products
      • 4.4.6.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.7 Respiratory infection testing products
      • 4.4.7.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.8 Tropical disease testing products
      • 4.4.8.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.4.9 Other infectious diseases testing products
      • 4.4.9.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.5 Coagulation testing products
    • 4.5.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.5.2 PT/INR testing products
      • 4.5.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.5.3 Activated clotting time (ACT/APTT) testing products
      • 4.5.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.6 Pregnancy and fertility testing products
    • 4.6.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.6.2 Pregnancy testing products
      • 4.6.2.1 Market size, by region, 2015 - 2026 (USD Million)
    • 4.6.3 Fertility testing products
      • 4.6.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.7 Tumor/Cancer marker testing products
    • 4.7.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.8 Urinalysis testing products
    • 4.8.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.9 Cholesterol testing products
    • 4.9.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.10 Hematology testing products
    • 4.10.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.11 Drug-of-Abuse (DoA) testing products
    • 4.11.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.12 Fecal occult testing products
    • 4.12.1 Market size, by region, 2015 - 2026 (USD Million)
  • 4.13 Other products
    • 4.13.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 5 Point of Care Testing Market, By Technology

  • 5.1 Key segment trend
  • 5.2 Lateral flow assays
    • 5.2.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.3 Dipsticks
    • 5.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.4 Microfluidics
    • 5.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.5 Molecular diagnostics
    • 5.5.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.6 Immunoassays
    • 5.6.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.7 Agglutination assays
    • 5.7.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.8 Flow-Through
    • 5.8.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.9 Solid phase
    • 5.9.1 Market size, by region, 2015 - 2026 (USD Million)
  • 5.10 Biosensors
    • 5.10.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 6 Point of Care Testing Market, By Prescription

  • 6.1 Key segment trend
  • 6.2 OTC testing
    • 6.2.1 Market size, by region, 2015 - 2026 (USD Million)
  • 6.3 Prescription-based testing
    • 6.3.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 7 Point of Care Testing Market, By Application

  • 7.1 Key segment trend
  • 7.2 Cardio metabolic testing
    • 7.2.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.3 Infectious disease testing
    • 7.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.4 Nephrology testing
    • 7.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.5 Drug-of-Abuse (DoA) testing
    • 7.5.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.6 Blood glucose testing
    • 7.6.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.7 Pregnancy testing
    • 7.7.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.8 Cancer biomarker testing
    • 7.8.1 Market size, by region, 2015 - 2026 (USD Million)
  • 7.9 Other applications
    • 7.9.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 8 Point of Care Testing Market, By End-use

  • 8.1 Key segment trend
  • 8.2 Hospitals
    • 8.2.1 Market size, by region, 2015 - 2026 (USD Million)
  • 8.3 Diagnostic centers
    • 8.3.1 Market size, by region, 2015 - 2026 (USD Million)
  • 8.4 Research laboratories
    • 8.4.1 Market size, by region, 2015 - 2026 (USD Million)
  • 8.5 Home-care settings
    • 8.5.1 Market size, by region, 2015 - 2026 (USD Million)
  • 8.6 Others
    • 8.6.1 Market size, by region, 2015 - 2026 (USD Million)

Chapter 9 Point of Care Testing Market, By Region

  • 9.1 Key regional trends
  • 9.2 North America
    • 9.2.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.2.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.2.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.2.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.2.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.2.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.2.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.2.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.2.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.2.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.2.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.2.7 U.S.
      • 9.2.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.2.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.2.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.2.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.2.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.2.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.2.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.2.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.2.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.2.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.2.8 Canada
      • 9.2.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.2.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.2.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.2.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.2.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.2.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.2.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.2.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.2.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.2.8.5 Market size, by end-use, 2015 - 2026 (USD Million)
  • 9.3 Europe
    • 9.3.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.3.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.3.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.3.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.3.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.3.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.3.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.3.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.3.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.3.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.3.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.7 Germany
      • 9.3.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.8 UK
      • 9.3.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.8.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.9 France
      • 9.3.9.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.9.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.9.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.9.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.9.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.9.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.9.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.9.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.9.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.9.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.10 Spain
      • 9.3.10.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.10.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.10.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.10.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.10.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.10.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.10.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.10.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.10.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.10.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.3.11 Italy
      • 9.3.11.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.3.11.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.3.11.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.3.11.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.3.11.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.3.11.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.3.11.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.3.11.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.3.11.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.3.11.5 Market size, by end-use, 2015 - 2026 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.4.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.4.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.4.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.4.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.4.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.4.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.4.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.4.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.4.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.4.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.4.7 China
      • 9.4.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.4.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.4.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.4.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.4.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.4.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.4.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.4.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.4.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.4.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.4.8 Japan
      • 9.4.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.4.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.4.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.4.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.4.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.4.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.4.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.4.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.4.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.4.8.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.4.9 India
      • 9.4.9.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.4.9.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.4.9.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.4.9.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.4.9.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.4.9.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.4.9.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.4.9.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.4.9.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.4.9.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.4.10 Australia
      • 9.4.10.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.4.10.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.4.10.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.4.10.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.4.10.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.4.10.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.4.10.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.4.10.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.4.10.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.4.10.5 Market size, by end-use, 2015 - 2026 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.5.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.5.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.5.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.5.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.5.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.5.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.5.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.5.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.5.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.5.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.5.7 Brazil
      • 9.5.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.5.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.5.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.5.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.5.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.5.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.5.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.5.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.5.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.5.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.5.8 Mexico
      • 9.5.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.5.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.5.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.5.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.5.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.5.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.5.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.5.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.5.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.5.8.5 Market size, by end-use, 2015 - 2026 (USD Million)
  • 9.6 Middle East and Africa
    • 9.6.1 Market size, by country, 2015 - 2026 (USD Million)
    • 9.6.2 Market size, by product, 2015 - 2026 (USD Million)
      • 9.6.2.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
      • 9.6.2.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
      • 9.6.2.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
      • 9.6.2.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
      • 9.6.2.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
    • 9.6.3 Market size, by technology, 2015 - 2026 (USD Million)
    • 9.6.4 Market size, by prescription, 2015 - 2026 (USD Million)
    • 9.6.5 Market size, by application, 2015 - 2026 (USD Million)
    • 9.6.6 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.6.7 South Africa
      • 9.6.7.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.6.7.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.6.7.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.6.7.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.6.7.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.6.7.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.6.7.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.6.7.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.6.7.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.6.7.5 Market size, by end-use, 2015 - 2026 (USD Million)
    • 9.6.8 Saudi Arabia
      • 9.6.8.1 Market size, by product, 2015 - 2026 (USD Million)
        • 9.6.8.1.1 Market size, by glucose monitoring, 2015 - 2026 (USD Million)
        • 9.6.8.1.2 Market size, by cardiometabolic testing products, 2015 - 2026 (USD Million)
        • 9.6.8.1.3 Market size, by infectious disease testing products, 2015 - 2026 (USD Million)
        • 9.6.8.1.4 Market size, by coagulation testing products, 2015 - 2026 (USD Million)
        • 9.6.8.1.5 Market size, by pregnancy and fertility testing products, 2015 - 2026 (USD Million)
      • 9.6.8.2 Market size, by technology, 2015 - 2026 (USD Million)
      • 9.6.8.3 Market size, by prescription, 2015 - 2026 (USD Million)
      • 9.6.8.4 Market size, by application, 2015 - 2026 (USD Million)
      • 9.6.8.5 Market size, by end-use, 2015 - 2026 (USD Million)

Chapter 10 Company Profiles

  • 10.1 Competitive dashboard
  • 10.2 Abaxis, Inc.
    • 10.2.1 Business overview
    • 10.2.2 Financial data
    • 10.2.3 Product landscape
    • 10.2.4 Strategic outlook
    • 10.2.5 SWOT analysis
  • 10.3 Abbott Laboratories
    • 10.3.1 Business overview
    • 10.3.2 Financial data
    • 10.3.3 Product landscape
    • 10.3.4 Strategic outlook
    • 10.3.5 SWOT analysis
  • 10.4 Accubiotech Co, Ltd.
    • 10.4.1 Business overview
    • 10.4.2 Financial data
    • 10.4.3 Product landscape
    • 10.4.4 Strategic outlook
    • 10.4.5 SWOT analysis
  • 10.5 ACON Laboratories, Inc.
    • 10.5.1 Business overview
    • 10.5.2 Financial data
    • 10.5.3 Product landscape
    • 10.5.4 Strategic outlook
    • 10.5.5 SWOT analysis
  • 10.6 Becton, Dickinson and Company
    • 10.6.1 Business overview
    • 10.6.2 Financial data
    • 10.6.3 Product landscape
    • 10.6.4 Strategic outlook
    • 10.6.5 SWOT analysis
  • 10.7 Biolytical Laboratories
    • 10.7.1 Business overview
    • 10.7.2 Financial data
    • 10.7.3 Product landscape
    • 10.7.4 Strategic outlook
    • 10.7.5 SWOT analysis
  • 10.8 BioMrieux SA
    • 10.8.1 Business overview
    • 10.8.2 Financial data
    • 10.8.3 Product landscape
    • 10.8.4 Strategic outlook
    • 10.8.5 SWOT analysis
  • 10.9 Bio-Rad Laboratories, Inc.
    • 10.9.1 Business overview
    • 10.9.2 Financial data
    • 10.9.3 Product landscape
    • 10.9.4 Strategic outlook
    • 10.9.5 SWOT analysis
  • 10.10 Danaher Corporation (HemoCue)
    • 10.10.1 Business overview
    • 10.10.2 Financial data
    • 10.10.3 Product landscape
    • 10.10.4 Strategic outlook
    • 10.10.5 SWOT analysis
  • 10.11 Dexcom, Inc
    • 10.11.1 Business overview
    • 10.11.2 Financial data
    • 10.11.3 Product landscape
    • 10.11.4 Strategic outlook
    • 10.11.5 SWOT analysis
  • 10.12 Dragerwerk Ag & Co
    • 10.12.1 Business overview
    • 10.12.2 Financial data
    • 10.12.3 Product landscape
    • 10.12.4 Strategic outlook
    • 10.12.5 SWOT analysis
  • 10.13 LifeScan IP Holdings, LLC
    • 10.13.1 Business overview
    • 10.13.2 Financial data
    • 10.13.3 Product landscape
    • 10.13.4 Strategic outlook
    • 10.13.5 SWOT analysis
  • 10.14 Medtronic
    • 10.14.1 Business overview
    • 10.14.2 Financial data
    • 10.14.3 Product landscape
    • 10.14.4 Strategic outlook
    • 10.14.5 SWOT analysis
  • 10.15 Meridian Bioscience, Inc
    • 10.15.1 Business overview
    • 10.15.2 Financial data
    • 10.15.3 Product landscape
    • 10.15.4 Strategic outlook
    • 10.15.5 SWOT analysis
  • 10.16 Nova Biomedical
    • 10.16.1 Business overview
    • 10.16.2 Financial data
    • 10.16.3 Product landscape
    • 10.16.4 Strategic outlook
    • 10.16.5 SWOT analysis
  • 10.17 Orasure Technologies, Inc
    • 10.17.1 Business overview
    • 10.17.2 Financial data
    • 10.17.3 Product landscape
    • 10.17.4 Strategic outlook
    • 10.17.5 SWOT analysis
  • 10.18 F Hoffmann-La Roche Ltd
    • 10.18.1 Business overview
    • 10.18.2 Financial data
    • 10.18.3 Product landscape
    • 10.18.4 Strategic outlook
    • 10.18.5 SWOT analysis
  • 10.19 Siemens Healthineers
    • 10.19.1 Business overview
    • 10.19.2 Financial data
    • 10.19.3 Product landscape
    • 10.19.4 Strategic outlook
    • 10.19.5 SWOT analysis
  • 10.20 Sysmex Corporation
    • 10.20.1 Business overview
    • 10.20.2 Financial data
    • 10.20.3 Product landscape
    • 10.20.4 Strategic outlook
    • 10.20.5 SWOT analysis
  • 10.21 Trinity Biotech
    • 10.21.1 Business overview
    • 10.21.2 Financial data
    • 10.21.3 Product landscape
    • 10.21.4 Strategic outlook
    • 10.21.5 SWOT analysis